On Wednesday, a joint study by Babson and Baruch Colleges reported that the average rate of early-stage entrepreneurial activity in the U.S. rose to nearly 13% last year, up from 7% in 2008 and the highest level in more than a decade.
And now, the drug, in combination with the chemotherapy Taxol, allows patients with early-stage breast cancer an average of four months without their disease progressing.